vs
微芯科技（MCHP）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是微芯科技的1.2倍（$1.4B vs $1.2B），瑞思迈净利率更高（27.6% vs 5.3%，领先22.3%），微芯科技同比增速更快（15.6% vs 11.0%），微芯科技自由现金流更多（$318.9M vs $311.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs -5.4%）
微芯科技（Microchip Technology）是美国知名上市半导体企业，主营微控制器、混合信号芯片、模拟芯片及闪存知识产权（Flash-IP）相关集成电路的研发、生产与销售，产品覆盖工业控制、汽车电子、消费电子、物联网等众多领域，在全球半导体细分市场拥有领先地位。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
MCHP vs RMD — 直观对比
营收规模更大
RMD
是对方的1.2倍
$1.2B
营收增速更快
MCHP
高出4.6%
11.0%
净利率更高
RMD
高出22.3%
5.3%
自由现金流更多
MCHP
多$7.7M
$311.2M
两年增速更快
RMD
近两年复合增速
-5.4%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.4B |
| 净利润 | $62.7M | $392.6M |
| 毛利率 | 59.6% | 61.8% |
| 营业利润率 | 12.8% | 34.6% |
| 净利率 | 5.3% | 27.6% |
| 营收同比 | 15.6% | 11.0% |
| 净利润同比 | 217.0% | 13.9% |
| 每股收益（稀释后） | $0.06 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCHPRMD
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $970.5M | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.3B | $1.2B |
净利润MCHPRMD
| Q4 25 | $62.7M | $392.6M | ||
| Q3 25 | $41.7M | $348.5M | ||
| Q2 25 | $-18.6M | $379.7M | ||
| Q1 25 | $-154.6M | $365.0M | ||
| Q4 24 | $-53.6M | $344.6M | ||
| Q3 24 | $78.4M | $311.4M | ||
| Q2 24 | $129.3M | $292.2M | ||
| Q1 24 | $154.7M | $300.5M |
毛利率MCHPRMD
| Q4 25 | 59.6% | 61.8% | ||
| Q3 25 | 55.9% | 61.5% | ||
| Q2 25 | 53.6% | 60.8% | ||
| Q1 25 | 51.6% | 59.3% | ||
| Q4 24 | 54.7% | 58.6% | ||
| Q3 24 | 57.4% | 58.6% | ||
| Q2 24 | 59.4% | 58.5% | ||
| Q1 24 | 59.6% | 57.9% |
营业利润率MCHPRMD
| Q4 25 | 12.8% | 34.6% | ||
| Q3 25 | 7.8% | 33.4% | ||
| Q2 25 | 3.0% | 33.7% | ||
| Q1 25 | -10.3% | 33.0% | ||
| Q4 24 | 3.0% | 32.5% | ||
| Q3 24 | 12.6% | 31.6% | ||
| Q2 24 | 17.7% | 31.2% | ||
| Q1 24 | 19.1% | 31.3% |
净利率MCHPRMD
| Q4 25 | 5.3% | 27.6% | ||
| Q3 25 | 3.7% | 26.1% | ||
| Q2 25 | -1.7% | 28.2% | ||
| Q1 25 | -15.9% | 28.3% | ||
| Q4 24 | -5.2% | 26.9% | ||
| Q3 24 | 6.7% | 25.4% | ||
| Q2 24 | 10.4% | 23.9% | ||
| Q1 24 | 11.7% | 25.1% |
每股收益（稀释后）MCHPRMD
| Q4 25 | $0.06 | $2.68 | ||
| Q3 25 | $0.03 | $2.37 | ||
| Q2 25 | $-0.09 | $2.58 | ||
| Q1 25 | $-0.29 | $2.48 | ||
| Q4 24 | $-0.10 | $2.34 | ||
| Q3 24 | $0.14 | $2.11 | ||
| Q2 24 | $0.24 | $1.97 | ||
| Q1 24 | $0.29 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $250.7M | $1.4B |
| 总债务越低越好 | $5.4B | $403.9M |
| 股东权益账面价值 | $6.6B | $6.3B |
| 总资产 | $14.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.82× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资MCHPRMD
| Q4 25 | $250.7M | $1.4B | ||
| Q3 25 | $236.8M | $1.4B | ||
| Q2 25 | $566.5M | $1.2B | ||
| Q1 25 | $771.7M | $932.7M | ||
| Q4 24 | $586.0M | $521.9M | ||
| Q3 24 | $286.1M | $426.4M | ||
| Q2 24 | $315.1M | $238.4M | ||
| Q1 24 | $319.7M | $237.9M |
总债务MCHPRMD
| Q4 25 | $5.4B | $403.9M | ||
| Q3 25 | $5.4B | $408.7M | ||
| Q2 25 | $5.5B | $658.4M | ||
| Q1 25 | $5.6B | $663.1M | ||
| Q4 24 | $6.7B | $662.9M | ||
| Q3 24 | $6.4B | $667.6M | ||
| Q2 24 | $6.2B | $697.3M | ||
| Q1 24 | $6.0B | $997.0M |
股东权益MCHPRMD
| Q4 25 | $6.6B | $6.3B | ||
| Q3 25 | $6.7B | $6.1B | ||
| Q2 25 | $6.9B | $6.0B | ||
| Q1 25 | $7.1B | $5.5B | ||
| Q4 24 | $6.0B | $5.3B | ||
| Q3 24 | $6.3B | $5.2B | ||
| Q2 24 | $6.4B | $4.9B | ||
| Q1 24 | $6.7B | $4.6B |
总资产MCHPRMD
| Q4 25 | $14.3B | $8.5B | ||
| Q3 25 | $14.5B | $8.3B | ||
| Q2 25 | $15.0B | $8.2B | ||
| Q1 25 | $15.4B | $7.6B | ||
| Q4 24 | $15.6B | $7.1B | ||
| Q3 24 | $15.6B | $7.2B | ||
| Q2 24 | $15.8B | $6.9B | ||
| Q1 24 | $15.9B | $6.8B |
负债/权益比MCHPRMD
| Q4 25 | 0.82× | 0.06× | ||
| Q3 25 | 0.80× | 0.07× | ||
| Q2 25 | 0.80× | 0.11× | ||
| Q1 25 | 0.80× | 0.12× | ||
| Q4 24 | 1.12× | 0.13× | ||
| Q3 24 | 1.02× | 0.13× | ||
| Q2 24 | 0.96× | 0.14× | ||
| Q1 24 | 0.90× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $341.4M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $318.9M | $311.2M |
| 自由现金流率自由现金流/营收 | 26.9% | 21.9% |
| 资本支出强度资本支出/营收 | 1.9% | 2.0% |
| 现金转化率经营现金流/净利润 | 5.44× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $819.9M | $1.8B |
8季度趋势，按日历期对齐
经营现金流MCHPRMD
| Q4 25 | $341.4M | $339.7M | ||
| Q3 25 | $88.1M | $457.3M | ||
| Q2 25 | $275.6M | $538.8M | ||
| Q1 25 | $205.9M | $578.7M | ||
| Q4 24 | $271.5M | $308.6M | ||
| Q3 24 | $43.6M | $325.5M | ||
| Q2 24 | $377.1M | $440.1M | ||
| Q1 24 | $430.0M | $402.0M |
自由现金流MCHPRMD
| Q4 25 | $318.9M | $311.2M | ||
| Q3 25 | $51.6M | $414.4M | ||
| Q2 25 | $257.7M | $508.2M | ||
| Q1 25 | $191.7M | $557.9M | ||
| Q4 24 | $253.4M | $288.0M | ||
| Q3 24 | $22.8M | $307.7M | ||
| Q2 24 | $304.2M | $415.2M | ||
| Q1 24 | $389.9M | $380.8M |
自由现金流率MCHPRMD
| Q4 25 | 26.9% | 21.9% | ||
| Q3 25 | 4.5% | 31.0% | ||
| Q2 25 | 24.0% | 37.7% | ||
| Q1 25 | 19.8% | 43.2% | ||
| Q4 24 | 24.7% | 22.5% | ||
| Q3 24 | 2.0% | 25.1% | ||
| Q2 24 | 24.5% | 33.9% | ||
| Q1 24 | 29.4% | 31.8% |
资本支出强度MCHPRMD
| Q4 25 | 1.9% | 2.0% | ||
| Q3 25 | 3.2% | 3.2% | ||
| Q2 25 | 1.7% | 2.3% | ||
| Q1 25 | 1.5% | 1.6% | ||
| Q4 24 | 1.8% | 1.6% | ||
| Q3 24 | 1.8% | 1.5% | ||
| Q2 24 | 5.9% | 2.0% | ||
| Q1 24 | 3.0% | 1.8% |
现金转化率MCHPRMD
| Q4 25 | 5.44× | 0.87× | ||
| Q3 25 | 2.11× | 1.31× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | 0.56× | 1.05× | ||
| Q2 24 | 2.92× | 1.51× | ||
| Q1 24 | 2.78× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCHP
| Mixed Signal Microcontrollers | $586.5M | 49% |
| Analog | $322.9M | 27% |
| Other Product Line | $276.6M | 23% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
